Mirae Asset Global Investments Co., Ltd. Immunovant, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Immunovant, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 6,603 shares of IMVT stock, worth $181,648. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,603
Previous 5,928
11.39%
Holding current value
$181,648
Previous $163,000
11.04%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding IMVT
# of Institutions
191Shares Held
78.7MCall Options Held
401KPut Options Held
354K-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.03MShares$193 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.88MShares$189 Million0.07% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.52% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$143 Million2.5% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...